news, journals and articles from all over the world.
Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy—a commonly used hormone injection—plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years. The findings were published in the peer-reviewed journal The Lancet.
Zulu Social Aid and Pleasure Club Presents Men’s Health Fair, Sponsored by Ochsner Xavier Institute of Health Equity and Research.
A Cleveland Clinic-led research team uncovered how tumors circumvent prostate cancer therapy and identified a promising new strategy for treatment. Findings were published in Proceedings of the National Academy of Sciences (PNAS). Antiandrogen strategies remain the backbone for advanced prostate…
Research underscores the need to subdivide Hispanics and other racial and ethnic groups to fully understand actual disparities. Brandon A. Mahal, M.D. In a massive study, clinical researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School…
Cedars-Sinai urology experts will present their latest advances in urologic medicine at the annual scientific meeting of the American Urological Association (AUA) in New Orleans May 13-16, 2022. Among over 2,200 abstracts, one by Alexandra Dubinskaya, MD, a female pelvic medicine and reconstructive surgery (FPMRS) specialist—Is It Time for FPMRS to Prescribe Vibrators?—was selected to be included in the 117th AUA press session on May 13, 2022, at 9 a.m. CT.
Henry Ford Health is the first in Michigan to offer Robotic High Intensity Focused Ultrasound (HIFU) for the treatment of localized prostate cancer. This non-surgical treatment option spares surrounding healthy tissue, while allowing for a quicker treatment time and recovery for the patient.
This tipsheet highlights the latest medical discoveries and faculty news at Cedars-Sinai. Links to full news releases are included with each item.
In a large study led by Yale Cancer Center, more men received a prostate-specific antigen or PSA test to detect prostate cancer following revisions to the recommendation by the U.S. Preventative Services Task Force on screening. The results also showed significant increases in PSA testing among older men, a group for whom screening is not routinely recommended.
Researchers have developed a new treatment to be used in combination with radiotherapy that could significantly improve treatment outcomes for men with locally advanced prostate cancer.
A new study from Washington University School of Medicine in St. Louis has identified an RNA molecule that suppresses prostate tumors. The scientists found that prostate cancers develop ways to shut down this RNA molecule to allow themselves to grow.
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on the use of enzalutamide in treating people with prostate cancer.
The immune checkpoint protein B7-H3 may be a promising new target for immunotherapy in treatment-resistant prostate cancers, according to two new studies led by researchers at the Johns Hopkins Kimmel Cancer Center. The studies were presented recently at the European Society for Medical Oncology (ESMO) 2021 Conference.
Cleveland Clinic researchers have shown for the first time that diet-associated molecules in the gut are associated with aggressive prostate cancer, suggesting dietary interventions may help reduce risk. Findings from the study were published in Cancer Epidemiology, Biomarkers & Prevention.
African American men are at the highest risk for both developing and dying from prostate cancer. It is essential that this population take preventative measures and seek appropriate treatment if diagnosed.
A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy. The study, which examined biopsy samples collected from three large, randomized clinical trials, indicates that physicians potentially can use genetic test scores to personalize treatment for men with the most aggressive form of prostate cancer. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Using fewer—but higher—doses of radiation to treat men with prostate cancer who had their prostates removed does not increase long-term side effects or lower their quality of life compared to conventional radiation treatment, a new, multi-institutional clinical trial shows.
Two research teams have developed new noninvasive tests that use either blood or saliva samples to diagnose cases of colorectal cancer or prostate cancer, respectively. Presented today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, these tests could facilitate screening efforts for colorectal cancer and allow clinicians to better distinguish early-stage prostate cancer from more benign prostate conditions.
As Prostate Cancer Awareness Month comes to a close, researchers want to circulate the message that some gene mutations linked to breast and ovarian cancer are also associated with prostate cancer.
Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies best suited to their disease.
New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer.
A paper detailing the method that led to the US Food and Drug Administration approval for PSMA PET imaging, which was led by UCLA and UCSF and their nuclear medicine teams, was recently published in JAMA Oncology.
For men with “low-risk” prostate cancer initially managed with active surveillance, cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Over the last decade, advancements have been made in the diagnosis and treatment of prostate cancer that are saving more lives. Tina Mayer, MD, a medical oncologist in the Prostate Cancer Program at Rutgers Cancer Institute of New Jersey shares some insight.
Tina Mayer, MD, medical oncologist in the Prostate Cancer Program at Rutgers Cancer Institute of New Jersey and an associate professor of medicine at Rutgers Robert Wood Johnson Medical School, shares information about prostate health.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts.
Physicians and scientists from UCLA will be joining thousands of urology experts on Sept. 10 to Sept. 13 for the virtual American Urological Association (AUA) Annual Meeting.
Nearly half of men initially managed with active surveillance for “low-risk” prostate cancer transition to definitive treatment – such as surgery or radiation therapy – within a few years after diagnosis, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA).
The Intermediate Clinical Endpoints of Cancer of the Prostate (ICECaP) working group, led by Dana-Farber Cancer Institute researchers, is being honored by the American Statistical Association (ASA) with the 2021 Statistical Partnerships Among Academe, Industry, and Government (SPAIG) Award.
Researchers led by the University of Michigan Rogel Cancer Center identified an inhibitor that showed promise against metastatic castration-resistant prostate cancer cells.
A new, University of Michigan-led study analyzing data from more than 850 patients across the state of Michigan found a commercially available genomic test known as Decipher Biopsy may help identify patients who are at high risk of prostate cancer progression.
New York, NY (July 23, 2021) — Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery , a…
Cardiovascular disease and cancer, the nation’s top two killers, share common ground like obesity and chronic inflammation, as well as a disproportionate impact on Black Americans. A new American Heart Association-funded center at the Medical College of Georgia is working…
What The Study Did: This study included 647 patients with untreated nonmetastatic prostate cancer (269 patients during the pandemic and 378 from before the pandemic). During the initial COVID-19 lockdown, only 1% of Black men underwent prostatectomy, while 26% of…
Most countries have not introduced nationwide prostate-cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine ,…
#ASTRO21 will be the first major medical conference in the city; a curated digital program also will be offered for remote attendees
Miniature 3D bone-like tissue models show effects of anti-androgens
Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds
New ‘nomogram’ opens the door to improved personalized treatments, UCLA-led study shows
Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a UCLA study.
Robotic prostate surgery pioneer Mani Menon, MD, is joining Mount Sinai and will serve as Chief of Strategy and Innovation in the Department of Urology for the Mount Sinai Health System. He will also serve as a Professor of Urology, Director of Education and Director of the Precision Prostatectomy Program in the Department of Urology at Icahn Mount Sinai and Center of Excellence for Prostate Cancer at The Tisch Cancer Institute.
FINDINGS Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a UCLA study led by Dr. Amar Kishan, assistant professor of…
The article by Dr. Biswa Mohan Sahoo et al. is published in Anti-Cancer Agents in Medicinal Chemistry, 2021
Black men most likely to benefit from advanced prostate cancer therapies are 11 percent less likely to get them than non-Black men. This happens despite apparent equal opportunities in obtaining health care services, a new study in American veterans shows.
Researchers report that about a quarter of localized prostate cancers may demonstrate immunologic traits that suggest a substantial number of patients with prostate cancer may benefit from immunotherapies.
Boston – In recent years, cancer immunotherapy has been effective in treating patients with immunogenic, or so-called “hot” tumors with increased levels of inflammation and the presence of immune cells in and around the tumors. Prostate cancer, however, is considered…
In a new study, a team of researchers uncovered new mechanisms underlying an important type of resistance to modern prostate cancer drugs called lineage plasticity, where castration-resistant prostate cancers undergo a deadly identity switch. They also outline a promising path to overcoming this form of resistance: BET bromodomain inhibitors.
Newly FDA-approved imaging agent now available for patients
An INRS team is investigating the relationship between body mass and the risk of developing cancer
Research from the University of Georgia has identified a protein that appears to prevent the cancer from spreading to and colonizing the bone, providing a new target for future therapeutics.
Researchers identified the protein responsible for cancer’s aggressiveness
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu